Researchers emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors vs an active comparator. (HealthDay News) — For ...
A new study published in the journal of Plos One showed that over the course of their lives, about one in three people with cystic fibrosis (CF) develop nephrolithiasis. The occurrence of ...
Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results